Clearside Biomedical (NASDAQ:CLSD) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
A number of other research firms have also recently issued reports on CLSD. JMP Securities reiterated an “outperform” rating and issued a $25.00 price objective on shares of Clearside Biomedical in a report on Monday, March 5th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $18.00 price objective (up from $15.00) on shares of Clearside Biomedical in a report on Tuesday, March 6th. Needham & Company LLC upped their price objective on Clearside Biomedical from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, March 6th. Zacks Investment Research cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Wedbush reiterated a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $19.50.
Clearside Biomedical (NASDAQ CLSD) opened at $13.00 on Friday. Clearside Biomedical has a fifty-two week low of $5.30 and a fifty-two week high of $15.06. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $329.45, a PE ratio of -6.13 and a beta of -5.48.
ILLEGAL ACTIVITY NOTICE: “Clearside Biomedical (CLSD) Upgraded by BidaskClub to “Hold”” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3254945/clearside-biomedical-clsd-upgraded-by-bidaskclub-to-hold.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.